ID: ALA5219416

Max Phase: Preclinical

Molecular Formula: C9H9N2O4PS

Molecular Weight: 272.22

Representations

Canonical SMILES:  O=C(CP(=O)(O)O)Nc1nc2ccccc2s1

Standard InChI:  InChI=1S/C9H9N2O4PS/c12-8(5-16(13,14)15)11-9-10-6-3-1-2-4-7(6)17-9/h1-4H,5H2,(H,10,11,12)(H2,13,14,15)

Standard InChI Key:  ITBYRUSLVYEHAB-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 272.22

Molecular Weight (Monoisotopic): 272.0021

AlogP: 1.41

#Rotatable Bonds: 3

Polar Surface Area: 99.52

Molecular Species: ACID

HBA: 4

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 1.66

CX Basic pKa:

CX LogP: 0.67

CX LogD: -1.82

Aromatic Rings: 2

Heavy Atoms: 17

QED Weighted: 0.73

Np Likeness Score: -1.88

References

1. He R, Wang J, Yu ZH, Moyers JS, Michael MD, Durham TB, Cramer JW, Qian Y, Lin A, Wu L, Noinaj N, Barrett DG, Zhang ZY..  (2022)  Structure-Based Design of Active-Site-Directed, Highly Potent, Selective, and Orally Bioavailable Low-Molecular-Weight Protein Tyrosine Phosphatase Inhibitors.,  65  (20.0): [PMID:36197449] [10.1021/acs.jmedchem.2c01143]

Source

Source(1):

• Scientific Literature